| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/11/2002 | WO2002053742A2 Proteins and nucleic acids encoding same |
| 07/11/2002 | WO2002053741A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/11/2002 | WO2002053740A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/11/2002 | WO2002053738A1 Novel proteins and dnas thereof |
| 07/11/2002 | WO2002053734A2 Methods and compositions for inhibiting neoplastic cell growth |
| 07/11/2002 | WO2002053733A2 Regulation of human b7-h2 protein |
| 07/11/2002 | WO2002053723A2 Degradation and detection of tse infectivity |
| 07/11/2002 | WO2002053719A2 Cytoskeleton-associated proteins |
| 07/11/2002 | WO2002053717A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/11/2002 | WO2002053716A2 Regulation of human ornithine decarboxylase |
| 07/11/2002 | WO2002053711A2 Use of transcription factor yb-1 in adenoviral systems |
| 07/11/2002 | WO2002053701A2 Epididymal lipocalin gene and uses thereof |
| 07/11/2002 | WO2002053700A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 07/11/2002 | WO2002053617A1 Linear block polymer |
| 07/11/2002 | WO2002053594A2 Inhibitors of memapsin 2 and use thereof |
| 07/11/2002 | WO2002053593A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/11/2002 | WO2002053592A1 Novel polypeptide and dna thereof |
| 07/11/2002 | WO2002053590A1 A novel fibrinolytic enzyme the polynucleotide encoding said polypeptide and the use thereof |
| 07/11/2002 | WO2002053584A1 Stabilized pharmaceutical composition in lyophilized form |
| 07/11/2002 | WO2002053581A2 Spliceosome mediated rna trans-splicing |
| 07/11/2002 | WO2002053580A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 07/11/2002 | WO2002053576A1 Viral delivery system for infectious transfer of large genomic dna inserts |
| 07/11/2002 | WO2002053288A2 A method for the manufacture of compositions containing low concentrations of salts |
| 07/11/2002 | WO2002053191A1 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof |
| 07/11/2002 | WO2002053190A2 Particles for inhalation having sustained release properties |
| 07/11/2002 | WO2002053177A2 Agents and methods for treating pain |
| 07/11/2002 | WO2002053175A2 Use of botulinum toxin for treatment of articular pathologies |
| 07/11/2002 | WO2002053174A2 Controlled release pharmaceutical systems |
| 07/11/2002 | WO2002053172A2 Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
| 07/11/2002 | WO2002053171A2 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity |
| 07/11/2002 | WO2002053170A2 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
| 07/11/2002 | WO2002053169A2 Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration |
| 07/11/2002 | WO2002053167A2 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect |
| 07/11/2002 | WO2002053142A2 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 07/11/2002 | WO2002053137A2 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 07/11/2002 | WO2002053136A1 Sustained release preparations |
| 07/11/2002 | WO2002053127A1 Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002053092A2 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 07/11/2002 | WO2002053017A2 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer |
| 07/11/2002 | WO2002052955A1 Nutritional and therapeutical preparations having antioxidant activity |
| 07/11/2002 | WO2002052934A2 Pesticidal and antiparasitic compositions |
| 07/11/2002 | WO2002043665A3 Ahf associated dispersion system and method for preparation |
| 07/11/2002 | WO2002034705A3 C-nitroso compounds and use thereof |
| 07/11/2002 | WO2002034119A3 Vaccine immunotherapy for immune suppressed patients |
| 07/11/2002 | WO2002032446A3 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils |
| 07/11/2002 | WO2002030970A3 Human histone deacetylase gene |
| 07/11/2002 | WO2002030889A3 A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
| 07/11/2002 | WO2002028349A3 Method of treating cancer using dithiocarbamate derivatives |
| 07/11/2002 | WO2002027019A8 Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| 07/11/2002 | WO2002026955A3 Human proteases and polynucleotides encoding the same |
| 07/11/2002 | WO2002024057A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2002019965A3 Heat shock response and virus replication |
| 07/11/2002 | WO2002019962A3 Therapeutic and cosmetic uses of heparanases |
| 07/11/2002 | WO2002014511A3 Regulation of human p2y1-like g protein-coupled receptor |
| 07/11/2002 | WO2002014346A8 Antimicrobial peptides isolated from fish |
| 07/11/2002 | WO2002012479A3 Zcys9: a member of the cystatin superfamily |
| 07/11/2002 | WO2002011666A3 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 07/11/2002 | WO2002010199A3 C3b/c4b complement receptor-like molecules and uses thereof |
| 07/11/2002 | WO2002008286A3 Zinc finger domain recognition code and uses thereof |
| 07/11/2002 | WO2002006454A3 Regulation of human carboxylesterase-like enzyme |
| 07/11/2002 | WO2002004610A3 Regulation of human dipeptidyl-peptidase iv-like enzyme |
| 07/11/2002 | WO2002000862A3 32447, a novel human acyltransferase and uses thereof |
| 07/11/2002 | WO2002000854A3 Regulation of human phosphodiesterase-like enzyme |
| 07/11/2002 | WO2001096375A3 33358, a novel human ankyrin family member and uses thereof |
| 07/11/2002 | WO2001091783A3 Methods and compositions for producing a neurosalutary effect in a subject |
| 07/11/2002 | WO2001085930A3 Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| 07/11/2002 | WO2001083781A3 14094, a novel human trypsin family member and uses thereof |
| 07/11/2002 | WO2001079445A3 Pluripotent cells comprising allogenic nucleus and mitochondria |
| 07/11/2002 | WO2001079274A3 Tuberculosis antigens and methods of use thereof |
| 07/11/2002 | WO2001078756A3 Agent for postoperative use after the removal of bone tumours |
| 07/11/2002 | WO2001076556A3 Lipid-based drug delivery systems against parasitic infections |
| 07/11/2002 | WO2001074389A3 Improved treatment of neovascularization |
| 07/11/2002 | WO2001068145A3 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 07/11/2002 | WO2001059094A3 Method of regulating transcription in a cell by altering remodeling of cromatin |
| 07/11/2002 | WO2001053331A3 Peptidomimetic modulators of cell adhesion |
| 07/11/2002 | WO2001046443A3 Proteases |
| 07/11/2002 | WO2001046383A9 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 07/11/2002 | WO2001045577A3 Intervertebral disc treatment devices and methods |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001040267A3 Proteoglycans and pharmaceutical compositions comprising them |
| 07/11/2002 | WO2001034225A3 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| 07/11/2002 | WO2001034205A3 Use of lytic toxins and toxin conjugates |
| 07/11/2002 | WO2001032920A3 Agents implicated in endometriosis |
| 07/11/2002 | WO2001031037A3 Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
| 07/11/2002 | WO2001030392A3 Delivery of proteins across polar epithelial cell layers |
| 07/11/2002 | WO2001029054A3 Medicaments for treatment of respiratory syncytial virus infections |
| 07/11/2002 | WO2001025438A3 Ifn-alpha homologues |
| 07/11/2002 | WO2001025273A3 Compositions and methods for wt1 specific immunotherapy |
| 07/11/2002 | WO2001024785A3 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 07/11/2002 | WO2001021213A3 Inhibition of secretion from non-neuronal cells |
| 07/11/2002 | WO2001021190A9 Treatment for narcolepsy |
| 07/11/2002 | WO2001017568A3 Bioconjugation in vivo to pulmonary or blood components |
| 07/11/2002 | WO2001017563A3 Integrin-mediated drug targeting |
| 07/11/2002 | WO2001016323A3 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 07/11/2002 | WO2001016322A3 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 07/11/2002 | WO2001012816A3 Porcine endovirus gag and env and diagnostic uses thereof |
| 07/11/2002 | WO2001012651A3 Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neural cell differentiation |
| 07/11/2002 | WO2001011335A9 Antiviral compounds that inhibit viral replication |